Skip to main content
Akeso, Inc. logo

Akeso, Inc. — Investor Relations & Filings

Ticker · 9926 ISIN · KYG0146B1032 LEI · 254900ECWYGR3QW5GF30 HKEX Manufacturing
Open in API
Filings indexed 334 across all filing types
Latest filing 2025-04-03 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9926

About Akeso, Inc.

http://www.akesobio.com

Akeso, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs globally. The company integrates comprehensive drug discovery capabilities, including target validation and antibody drug development. Akeso maintains a broad and innovative therapeutic portfolio, primarily concentrated in the fields of oncology and immunology. The company has successfully advanced multiple novel therapies, including five innovative drugs with approved indications, demonstrating its commitment to bringing breakthrough treatments to market. Akeso has notably developed a lung cancer drug that has garnered significant attention within the global biotech sector.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2025
Regulatory Filings Classification · 1% confidence The document is an HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities” for the month ended 31 March 2025. It is a mandatory regulatory filing detailing share capital structure and movements (authorized capital, issued shares, share options, RSU schemes, etc.), rather than an earnings release, share issue announcement, or annual/interim report. There is no material capital change announcement (e.g. new share issue) but rather a periodic compliance return. This fits best into the general Regulatory Filings category (RNS) as a fallback for miscellaneous mandated filings.
2025-04-03 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
Earnings Release Classification · 1% confidence The document is titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024” and provides key financial highlights (revenue, profit/loss), a summary of audit committee review and auditor agreement, and MD&A style commentary. It reads like a preliminary annual earnings announcement rather than a full statutory annual report (10-K) with full audited financial statements. Therefore, it fits the definition of an Earnings Release (initial announcement of periodical financial results). FY 2024
2025-03-30 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a brief announcement under Hong Kong Exchange rules. It does not contain financial results nor detailed report content; it solely notifies investors of the date of a Board meeting to consider and approve the year-end results and their publication. This fits the definition of a Report Publication Announcement (RPA) rather than the report itself or another category.
2025-03-19 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2025
Share Issue/Capital Change Classification · 1% confidence The document is the Hong Kong Exchange’s FF301 ‘Monthly Return for Equity Issuer’ under Chapter 19B, detailing movements in authorised/registered share capital, issued shares, treasury shares, share options, RSUs, convertibles and other share-related arrangements for the month. This is not an AGM presentation or earnings release but a formal regulatory filing on capital structure changes. It best fits the “Share Issue/Capital Change” category (Code: SHA) which covers announcements and documents related to share issues and capital changes.
2025-03-05 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2025
Regulatory Filings Classification · 1% confidence The document is a mandatory monthly return (Form FF301) submitted to the Hong Kong Exchange detailing movements in authorized, issued and treasury shares, share option schemes and other share capital arrangements for the month ended 31 January 2025. It is not an earnings release, annual or interim report, nor a meeting or dividend notice, but rather a periodic regulatory compliance filing directly to the exchange under Chapter 19B of the Listing Rules. This matches the fallback category for miscellaneous regulatory announcements (Regulatory Filings).
2025-02-06 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2024
Share Issue/Capital Change Classification · 1% confidence The document is a regular monthly listing return filed under HKEX Chapter 19B rules, detailing movements in authorised share capital, issued shares, share option exercises, and other share issuance arrangements. It is not an earnings release or AGM material but a formal reporting of share capital changes. This aligns with the “Share Issue/Capital Change” category.
2025-01-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.